Robotic-guided spinal surgeries reduce both complications and the number of revision surgeries needed, according to a new report released today by Mazor Robotics (NSDQ:MZOR).

The study shows that spinal surgeries performed using the company’s guidance system had a five-fold reduction in surgical complications. Such technology also contributed to a seven-fold reduction in revision surgeries versus freehand-based minimally invasive lumbar fusion surgeries, a Mazor news release indicates.

The study, which started in 2014, was designed to assess the clinical impact of robotic-guidance, compared to fluoro-guidance. The company indicated that 379 patients enrolled in the study, of which 287 were in the robotic-guided arm and 92 in the fluoro-guided control arm.

The results were collected from 10 surgeons in nine U.S. sites and disclosed at the North American Spine Society’s annual meeting in Florida.

Israel-based Mazor Robotics, founded in 2001, is a medical device company and manufacturer of a robotic guidance system. In 2016, it posted revenue of $36.3 million compared with $26.1 million in 2015.

In early October, Mazor Robotics shares ticked up after the company reported its preliminary third-quarter sales numbers and disclosed plans to  post sales of $17.2 million for the three months ending Sept. 30.

In September, the company closed a third, $40 million tranche as part of a deal with Medtronic (NYSE:MDT).